This study aims to investigate the effectiveness of combining KIR-ligand incompatibility (reducing inhibitory signals) with ex-vivo NK cell activation or ADCC stimulation (increasing activation signals) against melanoma cells. The gene discussed is KIR3DL1; the disease is melanoma.